Compare Commvault Systems Inc (CVLT) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Commvault Systems Inc vs Sanofi SA — how do they compare? Commvault Systems Inc trades at $157.25 (market cap $6.25B), while Sanofi SA trades at $40.07 (market cap $95.18B). The key difference: Sanofi SA is far larger — about 15.2× Commvault Systems Inc's market cap, and Sanofi SA pays a 6.01% dividend while Commvault Systems Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Commvault Systems Inc for 17 Days and Sanofi SA for 94 Days on average.
| CVLT | SNY | |
|---|---|---|
Market Cap | $6.25B | $95.18B |
Volume | 632,727 | 2,995,646 |
Sector | Technology | Health |
52-Week High | $176.52 | $52.34 |
52-Week Low | $75.18 | $39.51 |
Typical Hold Time | 17 Days | 94 Days |
Enterprise Value | $6.24B | $114.48B |
Dividend Yield | — | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CVLT trades at $157.25, up 4.64% today, with a bullish technical signal and strong institutional interest. The company has beaten earnings estimates for three consecutive quarters, with Q3 2026 results pending. Recent news highlights include achieving AWS Data Competency and expanding FedRAMP High authorization, reinforcing its cyber resilience leadership.
The outlook is positive, supported by analyst consensus and recent strategic wins, though high valuation multiples and a projected decline in net profit margin for 2026 present risks. Upside potential exists if earnings momentum continues, but investors should weigh premium valuations against growth sustainability.
Sanofi (SNY) trades at $40.07, down 0.32% on the day, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $1.21 exceeding the $1.10 estimate. Revenue for 2025 reached $46.72 billion, with a net income margin of 16.72%. Recent news highlights a significant $8 billion immunology alliance expansion with Regeneron, signaling strategic growth initiatives.
The outlook is mixed; solid profitability and a strategic partnership provide upside potential, but a projected net income decline to $4.0 billion in 2026 and bearish technical indicators pose risks. Analyst sentiment is cautiously optimistic with a 44% buy rating, though investors should monitor execution of new collaborations and patent expiration impacts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Commvault Systems Inc
Commvault provides enterprise-grade data protection and information management software. Its platform helps businesses manage, back up, and recover data across on-premises, cloud, and hybrid environments.
Read more on CVLT →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
